Related by context. All words. (Click for frequent words.) 84 multicentre randomized double 82 randomized multicenter 81 Phase III randomized 80 randomized double 78 multicenter randomized 77 randomized placebo controlled 76 placebo controlled randomized 76 multicenter randomized placebo controlled 76 controlled multicenter 75 multicentre randomized 74 prospective randomized multicenter 74 multicenter 74 double blinded randomized 73 double blinded placebo 73 placebo controlled 73 multicenter placebo controlled 73 double blind placebo 73 randomized controlled 73 multicentre 73 placebo controlled Phase 73 blind randomized placebo 73 prospective randomized placebo 72 blinded placebo controlled 72 placebo controlled Phase III 72 TMC# C# 72 Phase IIIb 72 multicenter multinational 72 prospective multicenter 71 prospective randomized 71 label multicenter 71 blind multicenter 71 multicenter Phase III 71 randomized Phase III 70 multicenter randomized controlled 70 blind randomized 69 Placebo controlled 69 multicenter prospective 69 comparing XIENCE V 69 prospective multicenter randomized 69 randomized 68 active comparator 68 masked placebo controlled 68 placebo controlled clinical 68 dose escalation trial 68 randomized multicentre 68 blind placebo 68 Randomized 68 label multicenter randomized 68 prospective observational 67 multicenter Phase II 67 multicenter clinical 67 prospective randomized controlled 67 Phase 1b clinical 67 phase IIb clinical 67 VICTOR E1 67 randomized controlled Phase 67 Phase Ib clinical 67 randomized controlled clinical 67 Phase 2b randomized 66 randomized blinded 66 Randomised 66 Phase 2b study 66 Phase III placebo controlled 66 Multicenter Randomized Double 66 multicenter phase 66 Randomized Evaluation 66 label dose escalation 66 NO# [002] 66 randomized blinded placebo 66 AIR CF2 66 phase IIb 66 Phase III multicenter 65 randomized Phase 65 Sorafenib HCC Assessment 65 TRANSFORMS 65 dose escalation study 65 blind placebo controlled 65 BRIM2 65 multicenter study 65 multinational multicenter randomized 65 randomized clinical 65 dose escalation Phase 65 ROCKET AF 65 nonrandomized 65 phase IIa clinical 65 TAXUS ATLAS 65 Placebo Controlled 64 multicenter Phase 64 phase IIa 64 Phase 1b 64 Multicenter 64 BR.# 64 ascending dose 64 blinded randomized 64 ENDEAVOR IV 64 randomized controlled multicenter 64 EURIDIS 64 Phase Ib 64 LUX Lung 64 ongoing Phase 1b 64 single ascending dose 64 Phase Ib II 64 Phase III randomized controlled 64 dyskinesia PD LID 64 Randomized Phase 64 randomized #:# 63 TG MV 63 AIR CF1 63 controlled dose escalation 63 HCV SPRINT 63 Phase #/#a 63 phase IIIb 63 dose escalation clinical 63 Initiated Phase 63 randomized multicenter trial 63 phase Ib 63 BRIM3 63 evaluating tivozanib 63 Phase 2a clinical 63 placebo controlled multicenter 63 multicenter randomized clinical 63 Randomized Controlled 63 Phase IIIb clinical 63 ascending doses 63 RE LY ® 63 Phase 1b trial 63 Phase IIb 63 Phase III confirmatory 63 Phase IIb clinical 63 Phase III clinical 63 label multicenter Phase 63 blinded randomized placebo controlled 63 Trial Evaluating 63 Myocardial Infarction Study 62 randomized Phase 2b 62 CLL8 62 Prospective Randomized 62 multicentre randomized controlled 62 placebo controlled studies 62 landmark ATHENA 62 Phase 2b clinical 62 ECASS 62 Randomized Phase II 62 dose dose escalation 62 Phase 2a trial 62 NSABP B 62 EDEMA3 62 Multicentre 62 Phase III randomized placebo 62 REALITY Trial 62 Phase 2b trial 62 #:# randomization 62 evaluating carfilzomib 62 safety tolerability pharmacokinetics 62 Randomized Placebo Controlled 62 PRECiSE 62 observer blinded randomized 62 placebo controlled dose escalation 62 viral kinetic 62 treatment naive genotype 62 dosing cohorts 62 SPIRIT FIRST 62 phase 2a 62 ASTEROID 62 Pivotal Trial 62 fosbretabulin 62 MEND CABG 62 CHAMPION PCI 61 Randomized Double Blind Placebo 61 Phase 2b 61 RE LY 61 Clinical Antipsychotic Trials 61 APEX PD 61 randomized Phase IIb 61 number NCT# ClinicalTrials.gov 61 prospectively randomized 61 multicentre prospective 61 dose escalation 61 Randomized Double blind 61 prospective nonrandomized 61 Parkinson disease levodopa induced 61 phase IIb study 61 Intervention Effectiveness 61 Phase 1a 61 GOUT 61 pharmacokinetics PK 61 Phase IIa clinical 61 dose cohorts 61 Phase Ia 61 pivotal Phase III 61 Controlled Trial 61 Phase 2a 61 Study Evaluating 61 substudy 61 treatment naïve genotype 61 AIR2 Trial 61 NCT# ClinicalTrials.gov 61 Phase Ib IIa 61 ExTRACT TIMI 61 BCIRG 61 blind randomized controlled 61 pharmacokinetic PK 61 ONTARGET 61 HCV RESPOND 2 61 Oral Fingolimod 61 prospective multicentre 61 Phase 1b dose escalation 61 Edge STudy 60 Carotid Revascularization Endarterectomy vs. 60 #mg QD [002] 60 placebo controlled trials 60 MIVI III 60 Initiate Phase 60 trials RCTs 60 multicentre study 60 FAME Study 60 randomized #:#:# 60 multiple ascending dose 60 dose regimens 60 LUMINATE 60 Randomized Clinical Trial 60 CATIE AD 60 Phase Ib study 60 randomized controlled trial 60 APTIVUS 60 Phase IIa 60 symptomatic BPH 60 HPTN 60 Phase IIa trial 60 interferon gamma 1b 60 somatostatin analog 60 randomized crossover 60 randomized placebo 60 controlled multicenter Phase 60 PD LID 60 Phase IIb trial 60 Phase III Clinical Trial 60 Trandolapril 60 Metabolic Efficiency 60 ritonavir boosted 60 Amrubicin 60 non inferiority 60 CALGB 60 Randomized Study 60 EchoCRT 60 phase Ib clinical 60 pharmacodynamic profiles 60 Prostate Lung Colorectal 60 Phase III 60 Endovascular Valve Edge 60 AIR CF3 60 ascending dose study 60 Pivotal Phase 60 metastatic hormone refractory 60 Phase IIIb study 60 ANCHOR trial 60 phase IIb trial 60 Phase 2b kidney transplant 60 Phase Ib clinical trials 60 nab paclitaxel 60 RAVEL 60 EQUATE OB 60 comparing alemtuzumab 60 EVEREST II 60 AVOREN 59 SCH # 59 NOX E# 59 registrational Phase 59 By JENNIFER LEARN 59 label dose titration 59 Phase 2b clinical trials 59 TAXUS V 59 blind multicentre 59 Acute Ischemic Stroke 59 Multiple Ascending Dose 59 relapsed refractory multiple myeloma 59 tanespimycin 59 ALLEGRO 59 Liraglutide Effect 59 CUSTOM II 59 noninferiority 59 EQUIP OB 59 pivotal Phase 59 CIMZIA TM certolizumab pegol 59 relapsing multiple sclerosis 59 Randomized Double Blind 59 mg BID 59 Multi Ethnic Study 59 randomized controlled clinical trials 59 RIBBON 59 STEALTH C 59 confirmatory Phase III 59 metastatic HRPC 59 LEXIVA r 59 RECORD1 59 multicenter randomized Phase III 59 Matrix Phase 2b 59 ADVANCE PD 59 ENDEAVOR II 59 EINSTEIN DVT 59 SPIRIT IV 59 mg RDEA# 59 prospectively defined 59 desvenlafaxine succinate 59 RESOLUTE 59 II Clinical Trial 59 ToGA 59 evaluating Vectibix 59 MADIT II 59 INSPIRE Trial Phase III 59 GetGoal Phase III 59 mg QD 59 comparator arm 59 subanalysis 58 evaluating REVLIMID 58 ZYBRESTAT fosbretabulin 58 SPIRIT III 58 rALLy clinical trial 58 mg administered orally 58 PRE SURGE 58 Completes Patient Enrollment 58 Phase 1b clinical trials 58 pharmacodynamics 58 International Verapamil SR 58 Completes Enrollment 58 GAMMAGARD 58 plus Copegus R 58 REVIVE Diabetes 58 TRITON TIMI 58 TAXUS IV 58 Phase 1a clinical 58 TAXUS VI 58 Phase III psoriasis 58 ZYBRESTAT 58 stage IIIB 58 TROPIC 58 Prostate AdenoCarcinoma Treatment 58 landmark ATHENA study 58 Left Ventricular Dysfunction 58 secondary efficacy endpoints 58 primary hypercholesterolemia 58 forodesine 58 ACTEMRA TM 58 lorcaserin Phase 58 telaprevir dosing 58 CLARITY TIMI 58 RELOVAIR ™ 58 dextromethorphan quinidine 58 Multicenter Phase 58 Phase IIa trials 58 mGluR5 negative 58 Randomized controlled 58 Sapacitabine 58 Combination REOLYSIN R 58 Pre RELAX AHF 58 Controlled Study 58 trastuzumab emtansine T DM1 58 XIENCE V Stent System 58 icatibant 58 Phase #b/#a clinical 58 safety tolerability pharmacokinetic 58 Remission Maintenance 58 virus HCV protease inhibitor 58 Initiates Phase II 58 KRN# 58 relapsed myeloma 58 investigational protease inhibitor 58 Phase IIb III 58 oral ridaforolimus 58 PRECISE 58 investigational oral 58 pharmacokinetic PK study 58 pharmacodynamic profile 58 FOLOTYN ® 58 relapsed MM 58 Phase 2b Clinical Trial 58 PET FROM 58 RADIANT 58 HCV NS5B polymerase 58 Zenvia ™ 58 Val HeFT 58 Phase IIb randomized 58 Pooled Analysis 58 RE SURGE 58 ORAL Sync 58 INCB# [001] 58 Raloxifene Evaluation MORE 58 Safinamide 58 HALTS 58 ALN VSP Phase 58 observational cohort study 58 CLARITY study 58 PEG IFN 58 COPERNICUS 58 Multicenter Randomized 58 CIMZIA TM 58 JAK inhibitor 58 Prospective Multicenter 57 DAPT Study 57 safety tolerability 57 Phase IIA 57 Tanespimycin 57 neratinib 57 melphalan prednisone 57 PFO migraine 57 PROPEL 57 RLAI 57 blind randomized multicenter 57 CALGB # [002] 57 STENT 57 ORACLE MS 57 galiximab 57 receptor tyrosine kinase inhibitor 57 Ovarian PLCO Cancer 57 designated HVTN 57 docetaxel Taxotere R 57 clinical trial 57 Phase IIb Trial 57 sirolimus eluting stent 57 PREVAIL 57 ACTIVE W 57 Pivotal Phase III 57 everolimus eluting stent 57 eluting stent 57 tolerability pharmacokinetics 57 Observational Study 57 PERSEUS 57 unfractionated heparin UFH 57 BOLDER II 57 Subgroup Analysis 57 DU #b 57 retinal vein occlusion induced 57 oral deforolimus 57 ENESTnd 57 ZACTIMA 57 ENVISION 57 Dose Ranging Study 57 pertuzumab 57 preclinical efficacy 57 Novel Oral 57 registrational trial 57 Thrombolysis 57 Prospective Randomized Trial 57 multicenter randomized Phase 57 CCR5 mAb 57 crizotinib PF # 57 evaluable patients 57 brivaracetam 57 stage IIIb IV 57 #mg BID [003] 57 confirmatory clinical 57 ARDIS 57 CONQUER 57 Polyp Prevention Trial 57 REYATAZ r 57 ABSORB clinical 57 PARTNER Trial 57 inhibitor RG# 57 NCCTG 57 GW# [003] 57 Adalimumab 57 pan HDAC inhibitor 57 recurrent glioblastoma multiforme 57 Pharmacokinetics PK 57 teriflunomide 57 MKC# MT 57 recurrent malignant glioma 57 huC# DM4 57 Zenvia Phase III 57 Phase III Pivotal 57 unstable angina UA 57 μg dose 57 DAPT 57 EXPLORE Xa 57 lexidronam injection 57 Placebo Controlled Trial 57 pivotal bioequivalence 57 AVONEX ® 57 NOXAFIL Oral Suspension 57 carboplatin paclitaxel 57 MADIT 57 Phase III VISTA 57 ABCSG 57 Ranolazine 57 blinded placebo 57 occlusion CRVO 57 REG2 57 Eluting Stent 57 Phase 2b Study 57 Pivotal Study 57 RRMS patients 56 reslizumab 56 Traficet EN 56 thorough QT 56 PreCISe 56 IMPACT DCM 56 prospective cohort 56 imetelstat GRN#L 56 PEGylated interferon beta 1a 56 PREZISTA r 56 MERLIN TIMI 56 Phase 2a Study 56 CAMMS# 56 Blinatumomab 56 placebo controlled clinical trials 56 Heart Failure Trial 56 Sym# 56 chemotherapy FOLFOX 56 davunetide intranasal AL 56 Stenting Trial CREST 56 Pharmacokinetic Study 56 Folfox 56 FOLFOX6 chemotherapy regimen 56 Patency 56 azilsartan medoxomil 56 PROMUS Element Stent 56 MIST II 56 Blind Placebo Controlled 56 Phase #b/#a 56 dasatinib Sprycel ® 56 plus prednisone 56 elotuzumab 56 Double Blind Placebo 56 Infarct 56 Tocilizumab 56 ID NCT# 56 Phase III ThermoDox 56 Denufosol 56 liposome injection 56 Meets Primary Endpoint 56 Phase III Clinical Trials 56 ug dose 56 liposomal formulation 56 histone deacetylase HDAC inhibitor 56 RG# ITMN 56 AVADO 56 pegylated interferon alfa 2a 56 PROTEGE 56 familial amyloidotic polyneuropathy FAP 56 QD dosing 56 Phase III Psoriasis 56 PROTECT AF 56 colesevelam HCl 56 Glatiramer Acetate 56 EORTC 56 metastatic castrate resistant 56 IIa trial 56 ATTRACT 56 null responder HCV 56 CARE HF 56 dexpramipexole 56 AIM HIGH 56 huN# DM1 56 Arimidex Tamoxifen Alone 56 trastuzumab Herceptin R 56 NCT# 56 IIa clinical 56 mg/m2 dose 56 Clinical Trial Evaluating 56 CML CP 56 adjunctive placebo 56 PRT# 56 Phase III pivotal 56 Initiates Phase 56 Randomized Controlled Trial 56 Betaferon ® 56 Clinical Trial Results 56 Prospective Randomized Double 56 XL# XL# XL# 56 oral FTY# 56 dose escalation phase 56 Screening Trial 56 Stenting Trial 56 Group RTOG 56 FREEDOMS 56 pomalidomide 56 patients undergoing percutaneous 56 viral kinetics 56 SUCCEED trial 56 cisplatin vinorelbine 56 phase IIb III 56 pegylated interferon alfa 2b 56 phase III isavuconazole 56 3TC lamivudine Epivir 56 registrational 56 Aplidin R 56 TELCYTA 56 Relapsing Multiple Sclerosis 56 Phase IIB 56 Neulasta R 56 laquinimod 56 GATTEX ® 56 bapineuzumab AAB 56 relapsing remitting multiple sclerosis 56 dirucotide MBP# 56 PCI ExTRACT TIMI 56 mg TID 56 Prostate Cancer Prevention 56 CAPRIE 56 diabetic neuropathic pain 56 STRIDE PD 56 humanized interleukin 6 56 Phase II 56 peginterferon alfa 2b 56 oral sapacitabine 56 MSI #F 56 ACCOMPLISH 56 XL# SAR# 56 TLK# 56 Commences Phase 56 VIRAMUNE XR 56 AZILECT R 56 sodium glucose cotransporter 56 TASKi2 56 Naive Patients 56 tolerability 56 CONQUER OB 56 APTIVUS r 56 Systemic Sclerosis 56 castrate resistant prostate cancer 56 systemic RNAi therapeutic 56 Pegasys ® 56 sunitinib malate 56 Asthma Intervention 56 zonisamide SR 55 oral rivaroxaban 55 COMFORT II 55 Anturol TM 55 PRoFESS 55 RIO Lipids 55 Group B CALGB 55 OLYMPIA registry 55 unique alkylating agent 55 fistulizing Crohn disease 55 phase III ACCLAIM 55 Efficacy 55 Severe Sepsis 55 Early Relapsing Multiple 55 Cloretazine ® 55 Communities ARIC study 55 sunitinib Sutent ® 55 ORMD 55 REVIVE 55 Seliciclib 55 retrospective observational study 55 randomized multicenter Phase III 55 eosinophilic asthma 55 efavirenz EFV 55 de novo kidney transplant 55 Elagolix 55 Aggressive Reduction 55 Betaferon R 55 Cardiac Allograft Rejection 55 Acute Myocardial Infarction 55 Phase Ib Clinical Trial 55 Hsp# Inhibitor 55 vicriviroc 55 administered subcutaneously 55 IMC A# 55 PEGINTRON TM 55 Aflibercept 55 8mg/kg 55 OPT CHF 55 Phase III Trial 55 opioid induced bowel dysfunction 55 MEND CABG II 55 venlafaxine XR 55 ZYBRESTAT TM 55 ritonavir boosted atazanavir 55 mg q#h 55 TO AVOID PREGNANCY WHILE 55 AVERROES 55 Adenoma Prevention 55 FOLPI 55 dabigatran etexilate 55 CERVARIX 55 allosteric modulator NAM 55 assessing T DM1 55 fostamatinib 55 REVIVE TA 55 CANCIDAS 55 Phase IIb trials 55 lintuzumab SGN 55 REVLIMID lenalidomide 55 Primary endpoints 55 subcutaneous formulation 55 sNDA submission 55 azathioprine monotherapy 55 HBeAg positive 55 COU AA 55 Degarelix 55 CCX# 55 polymerase inhibitor 55 dose pharmacokinetic 55 plus gemcitabine 55 bepotastine besilate nasal spray 55 e HEALING 55 Rosuvastatin 55 randomized discontinuation trial 55 Protease Inhibitor 55 dose cohort 55 TMC# r 55 ocular hypertension 55 HGS ETR1 55 Medidur TM FA 55 Clolar ® 55 oral prodrug 55 THAT ARE DIFFICULT TO 55 BRAF inhibitor 55 Presents Positive 55 CR# vcMMAE 55 longitudinal cohort study 55 subcutaneously administered 55 achieved statistical significance 55 Non Alcoholic Steatohepatitis 55 XIENCE V PROMUS Stent 55 #mg/day [001] 55 daily Infergen 55 Ranibizumab 55 ENDEAVOR III 55 Safety Tolerability 55 LibiGel Phase III 55 ENDEAVOR IV clinical 55 Phase 2a Clinical Trial 55 HGS# 55 non nucleoside inhibitor 55 ALSYMPCA 55 RoACTEMRA 55 telaprevir dosed 55 VNP#M 55 satraplatin Phase 55 Intervention Effectiveness CATIE 55 HGS ETR1 mapatumumab 55 NCIC CTG 55 EGFR HER2 55 Teriflunomide 55 induced macular edema 55 Initiates Phase III 55 novel VDA molecule 55 NEVO RES 55 Monotherapy 55 CYPHER ® Sirolimus eluting 55 ceftazidime 55 budesonide foam 55 Omacetaxine mepesuccinate 55 mcg QD 55 EmbraceAC 55 evaluable subjects 55 ENDEAVOR 55 Randomized Phase III 55 R#/MEM # 55 Demonstrates Positive 55 specific CCR9 antagonist 55 sequential dose escalation 55 darunavir ritonavir 55 bosentan 55 daunorubicin 55 dosage regimens 55 DIRECT Trial 55 PRIMO CABG 55 systemic juvenile idiopathic 55 Intervention Trial 55 selective phosphodiesterase 55 evaluable 55 paclitaxel poliglumex 55 Atherosclerosis MESA 55 lacosamide 55 HGS ETR2 55 antibody MAb 55 bortezomib Velcade R 55 composite endpoint 55 nucleoside analog 55 Acute Decompensated Heart Failure 55 Newly Diagnosed Multiple Myeloma 55 Phase III metastatic melanoma 55 tapentadol ER 55 Cell Lymphoma 55 alfa 2a 55 LHRH receptor positive 55 ABSORB trial 55 ACTEMRA 55 NATRECOR R 55 AERAS-#/Crucell Ad# 55 ADMIRE HF 55 observational cohort 55 Peginterferon 55 novel histone deacetylase 55 Successfully Completes Phase 55 rNAPc2 55 histologically confirmed 55 Neovascular AMD 55 estramustine 55 CELLO 55 Tarceva TM 55 PSN# [002] 55 unblinded 55 pain palliation 55 Eluting Coronary Stent System 55 erlotinib Tarceva ® 55 docetaxel Taxotere ® 55 mapatumumab 55 occlusion PAO 55 CCX# B 55 DEB# 55 Imprime PGG 55 Antiviral Activity 55 XIENCE V Everolimus Eluting 55 factorial design 55 placebo PBO 55 Board DSMB 55 Pharmacokinetic PK 55 DSMB 55 Dacogen injection 55 Diabetic Macular Edema 54 dosing cohort 54 Tolvaptan 54 Platelet Inhibition 54 IMA# 54 Daclizumab 54 NSABP C 54 TMC# [002] 54 boosted protease inhibitor 54 RE MODEL 54 trodusquemine 54 HDAC Inhibitor 54 pharmacodynamics PD 54 riociguat 54 XIENCE V demonstrated 54 MGd 54 opioid naive 54 Laquinimod 54 Augment Injectable 54 R lenalidomide 54 Alocrest 54 AEGR 54 Chronic Hepatitis C 54 Xelox 54 ACCLAIM 54 orally inhaled migraine 54 metastatic renal cell carcinoma 54 ERATO 54 IL# PE#QQR 54 pan histone deacetylase 54 CRLX# 54 #mg BID [002] 54 HORIZONS AMI trial 54 Double Blind Randomized 54 DASISION 54 Ozarelix 54 ALN HPN 54 Chronic Heart Failure 54 Phase #b/#a trial 54 infliximab monotherapy 54 evaluating Actimmune 54 Blind Placebo Controlled Trial 54 lead Aganocide compound 54 somatostatin analogue 54 retrospective cohort 54 Zemplar Capsules 54 ARCALYST ® rilonacept 54 Feasibility Trial 54 Pegasys plus Copegus 54 CTA# Injection 54 Multicenter Study 54 Long Term Efficacy 54 MATCHED 54 Dapagliflozin 54 TEMSO 54 Omacetaxine 54 efficacy tolerability 54 CAPACITY trials 54 perampanel 54 pegylated liposomal doxorubicin 54 leukemia AML 54 lopinavir r 54 GEM OS1 54 Antiviral Therapy 54 trial evaluating PRX# 54 FOLFIRI 54 BOLDER 54 evaluating Xcytrin 54 Wisconsin Sleep Cohort 54 rilonacept 54 FOLFOX 54 RezularTM 54 PRTX 54 peripherally acting 54 mcg BID 54 cisplatin gemcitabine 54 Alpha Tocopherol Beta Carotene 54 HORIZONS AMI 54 TKB# 54 atazanavir ritonavir 54 Sipuleucel T 54 bevirimat Study 54 Phase IIb Clinical Trial 54 ASSERT 54 receiving INTRON 54 sorafenib tablets 54 intravitreal insert 54 #mg BID [001] 54 CRx 54 investigational pan BCR 54 evaluating mipomersen 54 retrospective cohort study 54 Diabetic Macular Edema DME 54 GATTEX ™ 54 evaluating satraplatin 54 RSD# oral 54 RCW breast cancer 54 low dose cytarabine 54 antiretroviral naïve 54 Spectrum Pharmaceuticals Announces 54 acute PAO 54 First Patient Enrolled 54 alvespimycin 54 PHX# 54 Xeloda ® 54 EXPAREL TM 54 CALERIE 54 pharmacodynamic effects 54 tenofovir emtricitabine 54 longitudinal observational study 54 Achieves Primary Endpoint 54 posaconazole 54 mertansine 54 BiTE R 54 IIb clinical trial 54 SANTE 54 volociximab 54 AAG geldanamycin analog 54 HeFT 54 DDP# 54 Radiation Therapy Oncology 54 Deforolimus 54 HCD# [002] 54 Gynecologic Oncology Group 54 axitinib 54 Afatinib 54 multicentric 54 analgesic efficacy 54 EOquin TM phase 54 VICTOR E3 54 doxorubicin docetaxel 54 Obatoclax 54 sorafenib Nexavar ® 54 cell lymphoma CTCL 54 GLPG# 54 prospective observational cohort 54 hypoxia activated prodrug 54 randomized clinical trials 54 Parathyroid Hormone 54 YONDELIS R 54 Sirolimus Eluting Stent 54 landmark ATHENA trial 54 non resectable 54 MIRCERA 54 multicenter dose escalation 54 Microplasmin 54 prospective multicenter study 54 Protelos 54 PF # [001] 54 Testosterone MDTS ® 54 ADAGIO study 54 initiated Phase Ib 54 JZP 54 plus COPEGUS 54 MAGE A3 ASCI 54 ANDROMEDA 54 First Patient Dosed 54 Enzastaurin 54 IMPACT IMmunotherapy 54 DA VINCI 54 Intervention Trial GAIT 54 Cholesterol Levels SPARCL 54 MKC# 54 Akt inhibitor 54 SIMPADICO 54 MEK inhibitor 54 EOquin TM 54 ADP receptor antagonist 54 bupropion SR 54 biliary tract cancer 54 MKC# MKC# PP 54 VADT 54 Phase 2a clinical trials 54 hydroxymethyl coenzyme 54 Allovectin 7 ® 54 recurrent GBM 54 5 fluorouracil leucovorin 54 acute coronary syndromes ACS 54 dacarbazine 54 Taxotere ® 54 tolerated dose MTD 54 unresectable stage 54 CUSTOM III 54 Demonstrates Sustained 54 VITAL Trial 54 R# #mg BID